6 assets in Epithelioid Sarcoma

Therapeutic assets addressing Epithelioid Sarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Epithelioid Sarcoma	National Cancer Institute (NCI)	P1/2	CCC (48)
Epsametostat Epithelioid Sarcoma	Haihe Biopharma Co., Ltd.	P1/2	CCC (48)
Fludeoxyglucose Epithelioid Sarcoma	National Cancer Institute (NCI)	P1/2	CCC (48)
Tiragolumab Epithelioid Sarcoma	National Cancer Institute (NCI)	P1/2	CCC (48)
Zoledronate Epithelioid Sarcoma	University of Florida	P1/2	CCC (48)
Apg-5918 Epithelioid Sarcoma	Ascentage Pharma Group Inc.	P1	CC (43)